1-4 of 4
Saskia Litière
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group

Alexander W. Wyatt, Saskia Litiere, Francois-Clément Bidard, Luc Cabel, Lars Dyrskjøt, Chris A. Karlovich, Klaus Pantel, Joan Petrie, Reena Philip, Hillary S. Andrews, Paz J. Vellanki, Sofie H. Tolmeijer, Xenia Villalobos Alberu, Christian Alfano, Jan Bogaerts, Emiliano Calvo, Alice P. Chen, Rodrigo A. Toledo, Elisabeth G.E. de Vries, Lesley Seymour, Scott A. Laurie, Elena Garralda, for the RECIST ctDNA workshop group
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (22): 5034–5041.
https://doi.org/10.1158/1078-0432.CCR-24-1883
Published: 15 November 2024
View article titled, Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group
Open the PDF for Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group in another window
Journal Articles

Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response

Lalitha K. Shankar, Erich Huang, Saskia Litiere, Otto S. Hoekstra, Larry Schwartz, Sandra Collette, Ronald Boellaard, Jan Bogaerts, Lesley Seymour, Elisabeth G.E. deVries
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 143–153.
https://doi.org/10.1158/1078-0432.CCR-21-3143
Published: 04 January 2023
View article titled, Meta-Analysis of the Test–Retest Repeatability of [<sup>18</sup>F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response
Open the PDF for Meta-Analysis of the Test–Retest Repeatability of [<sup>18</sup>F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response in another window
Includes: Supplementary data
Journal Articles

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

Nicholas C. Turner, Judith Balmaña, Coralie Poncet, Theodora Goulioti, Konstantinos Tryfonidis, Aafke H. Honkoop, Gabriele Zoppoli, Evangelia Razis, Oskar T. Johannsson, Marco Colleoni, Andrew N. Tutt, William Audeh, Michail Ignatiadis, Audrey Mailliez, Olivier Trédan, Antonino Musolino, Peter Vuylsteke, Maria Jose Juan-Fita, Iain R.J. Macpherson, Bella Kaufman, Luis Manso, Lori J. Goldstein, Susan L. Ellard, István Láng, Kai Yu Jen, Virginie Adam, Saskia Litière, John Erban, David A. Cameron
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5482–5491.
https://doi.org/10.1158/1078-0432.CCR-21-0310
Published: 15 October 2021
View article titled, Niraparib for Advanced Breast Cancer with Germline <em>BRCA1</em> and <em>BRCA2</em> Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study
Open the PDF for Niraparib for Advanced Breast Cancer with Germline <em>BRCA1</em> and <em>BRCA2</em> Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study in another window
Includes: Supplementary data
Journal Articles

Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials

Olivier Mir, Nathan Touati, Michela Lia, Saskia Litière, Axel Le Cesne, Stefan Sleijfer, Jean-Yves Blay, Michael Leahy, Robin Young, Ron H.J. Mathijssen, Nielka P. Van Erp, Hans Gelderblom, Winette T. Van der Graaf, Alessandro Gronchi
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (5): 1479–1485.
https://doi.org/10.1158/1078-0432.CCR-18-2748
Published: 01 March 2019
View article titled, Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials
Open the PDF for Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials in another window
Includes: Supplementary data